Global Attention-Deficit Hyperactivity Disorder Market - 2022-2029

Global Attention-Deficit Hyperactivity Disorder Market - 2022-2029

Market Overview

Attention-Deficit Hyperactivity Disorder Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 7.0% during the forecast period (2022-2029).

Attention-deficit hyperactivity disorder (ADHD) is a disorder that is marked by an ongoing pattern of hyperactivity-impulsivity and inattention that interferes with functioning or development.

Market Dynamics

The increasing access to health insurance for mental health treatment and rising incidence of ADHD.

The increasing access to health insurance for mental health treatment is expected to drive market growth.

Health insurance is defined as insurance for future surgical or medical expenditures. It is a contract where an individual or group of people by paying a fee called the premium purchase in advance for their health coverage. Based on the type of plan, usually, the insured person is either required to pay for the health expenses from their pocket, which the insurance company then reimburses or the expenses are directly paid by the insurance provider who pays it to the service provider. Data from the National Mental Health Survey (NMHS) reveal that mental disorders are significantly higher in households with lesser income, limited employment, and low levels of education, thus making it evident that they have a greater vulnerability to mental disorders. At the same time, these same factors also limit their access to and utilization of mental health services.

The rising incidence of ADHD is expected to drive market growth.

The prevalence of ADHD is highly variable worldwide, ranging from as low as 1% to nearly 20%, depending on the diagnostic criteria and the assessment tools used. With an estimated worldwide-pooled prevalence of 5.3%, ADHD is the most prevalent mental disorder in children. ADHD (attention-deficit hyperactive disorder) is responsible for 0.06% of total years lost to disability and 0.02% of total DALYs. The majority of the burden due to ADHD occurs in childhood. The magnitude of the burden attributable to ADHD needs the attention of policymakers in terms of early intervention and treatment.

Attention-deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder in childhood and adolescence, affecting 2.2 to 17.8% of all school-aged children and adolescents. ADHD in children has been associated with a wide range of developmental deficits, including limitations of learning or control of executive functions and global impairments of social skills.

Side effects associated with ADHD drugs are expected to hamper market growth.

In reducing symptoms of ADHD, stimulant medications can be very effective, but some kids experience uncomfortable or harmful side effects. When side effects become a problem, doctors try to change the dosage, the release formula, or the type of medication a child takes. The goal is to understand what will benefit them with the least side effects. Trouble sleep may also be caused by kids being too stimulated at bedtime, often by doing something on the computer to calm themselves. Their ADHD may keep them awake if the medication has worn off.

Another ADHD medication, atomoxetine (Strattera), isn't a stimulant but has been linked to adults and irregular heartbeats. The FDA suggests people with a history of these problems stay away from others. ADHD drugs may be connected to some mental health issues, but it's rare. For instance, some people have reported behavior problems like aggression and hostility. In contrast, others developed symptoms of bipolar disorder. The FDA also warned that there's a slight risk that stimulant ADHD drugs could lead to symptoms of psychosis-like hearing things or mood swings and paranoia.

COVID-19 Impact Analysis

Due to several protocols, medical practices have been affected during the COVID-19 pandemic. The procedures for diagnosis and monitoring attention deficit hyperactivity disorder (ADHD) problems involved in this pandemic have been affected. As people are scared to undergo therapies for ADHD or even buy the medication due to the risk of COVID-19, there has been an impact on the attention deficit hyperactivity disorder (ADHD) market.

Industry Analysis

The attention-deficit hyperactivity disorder market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis/B>

Stimulants segment is expected to hold the largest market share in the attention-deficit hyperactivity disorder Market

Stimulants effectively manage ADHD symptoms such as short attention span, impulsive behavior, and hyperactivity. Many stimulants are available: short-acting (immediate-release), intermediate-acting, and long-acting. The commonly used treatment for Attention-Deficit Disorder/ Hyperactivity Disorder is stimulant therapy. Stimulants effectively manage ADHD symptoms such as impulsive behavior, short attention span, and hyperactivity. They may be used alone or in combination with behavior therapy. These drugs improve ADHD symptoms in about 70% of adults and 70% to 80% of children shortly after starting treatment. Improvements include reduced interrupting, fidgeting, and other hyperactive symptoms, home relationships, and improved task completion. Improvements in behavior and attention span usually continue as long as the medication is taken. However, social adjustment and school performance benefits have not yet been shown to endure over the long term.

Currently, the most commonly prescribed medications for ADHD are stimulant drugs (psychostimulants). Stimulants appear to boost and balance levels of brain chemicals called neurotransmitters. These medications help improve the signs and symptoms of inattention and hyperactivity, sometimes in a short period. Amphetamines include dextroamphetamine (Dexedrine),dextroamphetamine-amphetamine, and lisdexamfetamine (Vyvanse). Stimulant drugs are available in long-acting and short-acting forms. A long-acting patch of methylphenidate (Daytrana) is available that can be worn on the hip.

The pediatric and Adolescents segment will dominate the attention deficit hyperactivity disorder (ADHD)

Estimates suggest that about 4% to 12% of children have ADHD. Boys are 2 to 3 times more likely to have ADHD of the hyperactive or combined type than girls. In the U.S, around 6.1 million children (9.4 percent) between the ages of 2 to 17 are estimated to have been diagnosed with attention deficit hyperactivity disorder (ADHD or ADD).

The American Psychiatric Association (APA) stated that 5 % of children in America have ADHD. But the Centers for Disease Control and Prevention (CDC) put the number at more than double the APAs. According to the CDC, 11 percent of American children, ages 4 to 17, have an attention disorder. Approximate 8.4% of children and 2.5% of adults have ADHD. ADHD is first identified in school-aged children when it leads to disruption in the classroom or problems with schoolwork. ADHD from childhood is a chronic health problem with a significant risk for mortality, the persistence of ADHD, and long-term morbidity in adulthood. Though ADHD has been reported to affect 4.4% of adults, the estimation of the persistence of ADHD from childhood to adulthood has varied widely, ranging from 6% to 66.

Retail Pharmacies segment will dominate the attention deficit hyperactivity disorder (ADHD)

Attention-deficit hyperactivity disorder (ADHD) medications are subject to abuse, misuse, and diversion. Obtaining ADHD prescriptions from multiple prescribers or filled across multiple pharmacies, known as ‘doctor shopping,’ may reflect such unsanctioned use. No clinical guidelines exist to guide dosing or indications for use, making it difficult to have a standardized treatment approach, especially with differing state regulations. Instead of traditional pharmacies, patients seeking marijuana for medicinal use often go to dispensaries. Some dispensaries focus on stocking and selling only recreational or medicinal products, while others offer both.

Retail Pharmacies would be the safest place for dispensing attention-deficit hyperactivity disorder (ADHD) medications. Pharmacists are experts in medication and play a significant role in dispensing and monitoring medication to ensure safe and optimal use. Dispensing, like other ADHD medications, through a pharmacy is the safest option.

Geographical Analysis

North American region is expected to hold the largest market share in the global attention-deficit hyperactivity disorder market.

A behavioral disorder Attention-deficit hyperactivity disorder (ADHD) affects up to 1 in 20 children in the USA. The predominance of American research into this disorder over the past 40 years has led to the impression that ADHD is largely an American disorder and is much less prevalent elsewhere.

ADHD isn’t just a childhood disorder. About 4% of American adults over the age of 18 contend with ADHD behaviors daily. In adulthood, it’s diagnosed equally between males and females. During their lifetimes, 13% of men will be diagnosed with ADHD, while just 4.2% of women will be diagnosed. Current prevalence rates of ADHD vary between states, with Nevada having the lowest rate at 4.2% and Kentucky having the highest rate of 14.8%. In addition, due to the launch of products by regional players. For instance, Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., received U.S. regulatory approval in March 2019. Food and Drug Administration (FDA) for Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII for the treatment of attention deficit hyperactivity disorder (ADHD) in patients six years of age and older. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the attention-deficit hyperactivity disorder market are Pfizer Inc., Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Johnson & Johnson, UCB S.A., Hisamitsu Pharmaceutical Co., Inc., Purdue Pharma L.P. and Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.:

Overview:

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for treating central nervous system (CNS) diseases. Their extensive expertise in product development has been built over the past 30 years. Initially as a standalone development organization, then as a U.S. subsidiary of Shire plc is Supernus Pharmaceuticals Inc. They market products in the United States through their specialty sales force and seek strategic collaborations with other pharmaceutical companies to license products outside the United States.

Product Portfolio:

The company is developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD in adults, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Key Development:

The U.S. Food and Drug Administration (FDA) approved Qelbree, the first new non-stimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents in more than 10 years. Manufactured by Supernus Pharmaceuticals, Inc. Qelbree (viloxazine extended-release capsules) is a selective norepinephrine reuptake inhibitor—a class of drugs often used to treat anxiety and depression, and sometimes ADHD. Qelbree is approved to treat young people with ADHD between the ages of 6 and 17 years.

The global attention-deficit hyperactivity disorder market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.